The botanical supplement industry has witnessed an unprecedented surge in attention surrounding Ashwagandha (Withania somnifera) over the past year. This surge has been driven by regulatory scrutiny, scientific inquiry, and widespread media coverage. However, much of the industry commentary has distilled this complex landscape into an oversimplified narrative: that Ashwagandha root represents the traditional and authentic form, while the leaf is associated with adulteration and safety concerns, and that a simple "total withanolides" percentage can serve as a definitive measure of quality. This simplified story, while appealing in its clarity, fails to align with the scientific evidence and the nuanced realities of this ancient herb.
The core issue facing Ashwagandha in the marketplace is not a lack of scientific understanding regarding its safety, manufacturing, or composition, but rather a pervasive problem of inconsistency in its application and regulation. With nearly 200 clinical and safety studies examining both root and leaf products, the scientific community possesses a wealth of knowledge on Ashwagandha, surpassing that of many other botanical ingredients. Yet, these established principles of quality and safety have not been uniformly applied across the diverse global market.
Ashwagandha’s Evolving Regulatory Landscape
The regulatory decisions concerning Ashwagandha, like any natural product, carry significant implications for a wide array of stakeholders, including farmers, processors, manufacturers, exporters, brands, retailers, and ultimately, consumers. Furthermore, these decisions often influence regulatory bodies in other countries, creating a ripple effect throughout the international trade of botanical ingredients. This interconnectedness underscores the critical need for regulatory frameworks to be grounded in comprehensive evidence rather than simplistic narratives.
A prime example of this regulatory complexity unfolded in India. In April of this year, the Food Safety and Standards Authority of India (FSSAI) issued an advisory that declared only Ashwagandha roots and their extracts permissible under India’s food regulations. This was closely followed by a directive from India’s Ministry of Ayush concerning the use of Ashwagandha leaf within the country. These pronouncements were particularly perplexing as they appeared to be enacted without a thorough review of the scientific evidence supporting the use of Ashwagandha leaf, which, as research indicates, possesses substantial clinical and safety data.
The media’s portrayal of these actions often characterized the "leaf ban" as a global and permanent prohibition. However, the reality on the ground proved to be far more fluid. In India, several responsible companies contested these directives, leading to the Karnataka High Court granting interim relief, effectively pausing the enforcement of the advisory while legal proceedings continue. Reliable sources from India indicate that while the directive remains on paper, the High Court’s intervention has significantly neutralized its impact, allowing leaf products to remain available in the market. Reports suggest internal divisions within the involved agencies, questioning whether the damage to their reputation, the impact on exports, and the hardship inflicted on farmers were justified.
Market data from Neemuch, a significant trading hub for Ashwagandha, further challenges the efficacy of these restrictive measures. Recent data does not indicate a substantial shift in the market towards roots following the advisory on leaf use. Leaf products continued to be traded, albeit with a temporary absence in tracking data from Neemuch in the months immediately following the advisory. Furthermore, average root prices in September 2026 remained lower than those in September 2025, offering little evidence to suggest that the restriction on leaf strengthened demand for root. Concurrently, suppliers and traders of substandard products appear to have maintained their ability to operate and export, underscoring a persistent challenge in regulatory enforcement.
The regulatory environment in Europe is also undergoing evolution. The Netherlands, for instance, had considered a broader prohibition on Ashwagandha following a 2024 safety assessment by the Dutch National Institute for Public Health and the Environment (RIVM). However, the Dutch Ministry subsequently indicated that the proposed ban on Ashwagandha would likely be rescinded pending a new RIVM assessment of root products based on additional scientific evidence. For the time being, leaf products continue to be treated differently. These instances highlight how arbitrary regulatory scrutiny can generate considerable confusion and unintended negative consequences for all parties involved.
Clarifying the Role of Leaf and Withaferin-A
A critical point of contention revolves around the presence of Ashwagandha leaf and the compound Withaferin-A. It is crucial to distinguish between a legitimate quality and labeling issue – such as a product being labeled as root but containing undeclared leaf – and the inherent presence of leaf material. The latter does not automatically equate to adulteration.
Withaferin-A, a withanolide naturally occurring in both Ashwagandha root and leaf, has unfortunately become a focal point of unwarranted suspicion. This compound has been present, in varying concentrations, across a wide range of characterized root, leaf, and root-and-leaf preparations that have been evaluated in clinical and toxicological research. While it is acknowledged that some suppliers may add leaf material to artificially inflate "total withanolide" levels, and that higher concentrations of Withaferin-A can indeed indicate the presence of leaf, the notion that this compound possesses questionable safety is not supported by scientific evidence.
Products that are exclusively root, a combination of root and leaf, or other specific preparations represent distinct materials. Each should be accurately identified, appropriately characterized, and supported by evidence relevant to the specific material being sold. The approach to safety assessment must be equally tailored to the product in question.
Recent published safety studies on Ashwagandha leaf underscore the problematic nature of prevailing narratives. A 2026 toxicological evaluation of an aqueous root-and-leaf extract (Sensoril) demonstrated excellent safety, reporting a 90-day no-observed-adverse-effect-level (NOAEL) of 4,000 mg/kg/day in rats. Another study, published concurrently, on a standardized root-and-leaf extract (Shoden), found no clinically significant changes in any safety parameters. Furthermore, a Phase 1 trial conducted in 2026 involving patients with advanced non-small cell lung cancer found an Ashwagandha leaf extract to be safe and well-tolerated. These findings are part of a growing body of evidence, with dozens of studies already published on root and leaf preparations, that collectively support the safety of various Ashwagandha forms when properly studied and characterized.
Addressing the "Ashwagandha Testing Problem"
A common misconception is that the industry is still awaiting scientific breakthroughs to resolve an "Ashwagandha testing problem." This is inaccurate. Robust analytical methods are already available. The U.S. Pharmacopeia (USP) and AOAC International have established methods for Ashwagandha root and root extracts. Additionally, third-party laboratories, such as Alkemist Labs, offer validated methods for both root and leaf preparations. The industry also benefits from established method-performance requirements, reference standards, and method validation guidances. It is anticipated that compendial methods for materials containing Ashwagandha leaf will also be developed.
The real challenge lies in ensuring that all stakeholders understand precisely what is being measured and can reliably reproduce the results. This becomes particularly critical when products compete based on a "percent withanolides" label claim. The industry continues to grapple with fundamental questions: Which specific withanolides are being quantified? What analytical method is being employed? What reference standards are being used? And how are the results being calculated? The absence of standardized answers to these questions creates significant ambiguity.
The Implications of Product Comparison
A December 2025 paper by Avula and colleagues at the University of Mississippi provided a compelling illustration of this inconsistency. The researchers compared 25 commercial Ashwagandha products using approaches based on British Pharmacopoeia (BP) and USP standards. Their findings revealed substantial variation: over 44% of the products failed BP criteria, 60% failed USP criteria, and a mere 10 out of the 25 met both.
It is important to note that none of the analyzed products were labeled as conforming to USP or BP method requirements. Different extracts can legitimately possess distinct chemical profiles, and analytical methods themselves have inherent limitations. The critical takeaway from such studies is that product variations exist and should be characterized rather than obscured by a single, often misleading, numerical claim. This is precisely why sophisticated analytical techniques like high-performance liquid chromatography (HPLC) and its derivatives are employed; they provide a chemical "fingerprint" that identifies specific constituents within a sample.
Despite the substantial market growth of Ashwagandha, now valued at approximately $1.5 billion, fundamental questions about product composition persist. The ultimate goal of testing should be to verify quality and composition, not to create a superficial appearance of compliance.
The Business Imperative for Stronger Standards
Beyond regulatory and scientific considerations, there is a compelling business rationale for establishing stronger standards for Ashwagandha. Companies that are already investing heavily in quality control and scientific research are often the most vocal advocates for more robust industry standards.
When a diluted or poorly characterized product can carry the same label claim as one meticulously manufactured, responsible companies face significant disadvantages. They bear the cost of diligent production, only to be undercut by unscrupulous competitors. This also leads to consumers not receiving the expected benefits from products they have purchased, eroding trust in the market. In essence, weak standards inadvertently subsidize poor practices and empower less scrupulous market participants.
In response to these challenges, the Ashwagandha Standards Alliance (ASA) has emerged as a collaborative initiative. The ASA brings together responsible Ashwagandha producers, including prominent companies like Sabinsa, Kerry, Arjuna Natural, and Cepham, along with a growing number of reputable brands and laboratories, to address critical industry issues and promote the development of standardized practices.
A Broader Perspective: Ashwagandha as a Precedent
The complex situation surrounding Ashwagandha is not an isolated incident but rather a microcosm of broader challenges facing the entire botanical extract industry. The same questions regarding standardization, accurate characterization, and evidence-based regulation are equally relevant to other widely used botanicals such as turmeric, ginkgo, green tea, saffron, bilberry, and elderberry, among countless others.
During a recent speaking engagement in India, a region with a deep historical and industrial connection to Ashwagandha, the author was reminded of the collective responsibility to honor both the people involved in the cultivation and production of these botanicals and the plants themselves. This responsibility necessitates getting the narrative right.
Moving forward, the industry must strike a balance between respecting traditional knowledge and demanding empirical evidence. Modern scientific advancements should be embraced, while acknowledging the limitations of simplistic self-reported metrics. Uncertainty where it exists must be openly admitted. Most importantly, the industry must commit to a thorough understanding of each plant, to truthful and accurate descriptions of its products, and to leaving the market stronger and more reliable than it was found.
If these principles are embraced, the implementation of stricter standards will not pose a threat to the Ashwagandha market; rather, they will serve as its most crucial protector, fostering trust, ensuring efficacy, and safeguarding the integrity of this valuable botanical for the benefit of all stakeholders.
